AGIO•benzinga•
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years
Summary
Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 13, 2025 by benzinga